Fluorene HSC Expansion Media for Potency Maintenance

The patent changes the chemical parameters of the culture medium by incorporating fluorene derivatives (compounds of Formula I) with specific molecular structures and properties. These compounds modify the biochemical environment to sustain HSC potency and prevent differentiation, directly addressing the limitation of classical cytokines that cause HSCs to lose potency within a week.

The patent applies preliminary action by expanding HSCs in the laboratory before therapeutic use. By incorporating fluorene derivatives into the culture medium, the method enables aggressive expansion of HSCs from single cord units, allowing one cord to generate multiple therapeutic doses through pre-expansion in culture.

The patent enables copying of HSCs from easily accessible peripheral blood sources (including non-mobilized peripheral blood) into expanded cultures. By using fluorene derivative-containing media, the method allows generation of therapeutically relevant HSC numbers from sources that would normally be insufficient, effectively copying and amplifying the cellular material.

The patent employs fluorene derivatives as temporary, non-transmissible chemical agents that provide aggressive expansion signals during the culture period but do not remain in the final therapeutic product. These compounds act as disposable catalysts that enable high-efficiency expansion without persisting in the patient, thereby enhancing productivity while mitigating safety concerns.